An open labelled, multi-center, non-comparative, interventional, prospectiveclinical study to evaluate efficacy and safety of Clenscicap in healthy participants.

Transformative Learning Solutions Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年7月25日

试验速览

暂无简介。

•Cohort A:-
•1.Subjects with known tuberculosis, Hepatitis B and C, HIV, ischemic heart disease, cancer, Kidney stone, Urinary tract infection, kidney failure, chronic liver diseases.
•2. Subjects with any other investigational product within 1 month prior to randomization.
•3.Subjects with diabetes mellitus and hypertension taking regular medications
•4.Pregnant and lactating women
•5.Subjects with significant abnormal laboratory parameters
•6.Known hypersensitivity to any of the ingredients of CLENSCICAP
•7.Other conditions, which in the opinion of the investigators, make subject unsuitable for enrolment or could interfere with his/her participation in, and completion of the study.
•Cohort B:-
•1.Subjects with known tuberculosis, hepatitis B and C, HIV, ischemic heart disease, cancer, kidney failure, chronic liver diseases,
•2.Subjects having jaundice or any other symptom of active hepatitis
•3.Subjects with any other investigational product within 1 month prior to randomization.
•4.Subjects with diabetes mellitus and hypertension taking regular medications
•5.Pregnant and lactating women
•6.Subjects with any significant abnormal laboratory parameters
•7.Known hypersensitivity to any of the ingredients of Clensicap Capsule.
•8.Other conditions, which in the opinion of the investigators, make subject unsuitable for enrolment or could interfere with his/her participation in, and completion of study.

发起方